AIM ImmunoTech Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Unless stated otherwise, financial amounts below are in millions of dollars. AIM is a clinical-stage immunopharma company focused primarily on Ampligen (rintatolimod); it also owns Alferon N Injection. Ampligen is not FDA-approved or marketed in the United States. It is approved in Argentina for severe CFS, but commercial distribution there remains subject to final inspection and release testing.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0.046 | $0.021 | $0.137 | $0.085 |
| Research and development | $2.734 | $1.372 | $7.739 | $4.883 |
| General and administrative | $5.439 | $5.170 | $10.280 | $9.569 |
| Operating loss | $(8.157) | $(6.521) | $(17.912) | $(14.367) |
| Net loss | $(7.816) | $(6.385) | $(16.386) | $(15.056) |
| Basic and diluted loss per share | $(0.16) | $(0.13) | $(0.34) | $(0.31) |
- Revenue was from the Ampligen cost-recovery program, principally increased use in the AMP-511 study. Revenue remains immaterial relative to operating costs; conventional operating margins are not meaningful.
- For the nine months, cash used in operating activities was $11.509 million, versus $10.039 million in 2022. Investing activities used $0.618 million, compared with $7.625 million provided in 2022; financing provided $0.338 million.
- At September 30, cash and cash equivalents were $15.264 million and marketable investments were $7.167 million, totaling $22.431 million. Cash alone declined from $27.053 million at December 31, 2022. Management cited operating burn as the main driver of the decline.
- Current assets were $22.742 million and current liabilities $4.716 million. Total liabilities were $5.259 million, including $0.750 million of operating lease liabilities; the filing reports no borrowings or conventional debt.
- Total assets were $27.861 million and stockholders’ equity $22.602 million. Common shares outstanding were 48.797 million at quarter-end and 48.842 million on November 12, 2023.
Material changes versus prior periods
- Q3 net loss increased $1.431 million, or 22%; nine-month net loss increased $1.330 million, or 9%.
- Nine-month R&D expense rose $2.856 million, chiefly from higher manufacturing costs and clinical-trial expense. G&A rose $0.711 million, primarily from professional fees, partly offset by lower stock compensation.
- Lower investment losses and higher interest and other income partly offset increased operating expenses. Nine-month loss on investments fell to $0.201 million from $1.769 million; interest and other income increased to $0.811 million from $0.296 million. The company also recorded a $0.900 million gain from sale of New Jersey tax operating losses.
- Cash used in operations increased by $1.470 million year over year. Marketable-investment sales were substantially lower than in the prior-year period, when investing activities included $9.082 million of proceeds from sales.
Outlook, developments, and risks
- Management said existing resources were expected to fund anticipated operating needs and current clinical trials for approximately 16 months from September 30, 2023. This is not a guarantee; the company may need additional financing, and equity issuance could dilute shareholders. The $8.5 million equity distribution facility had generated approximately $0.209 million gross proceeds through September 30.
- The Phase 2 AMP-518 post-COVID study reached planned enrollment of 80 participants. The company expected to complete last-subject dosing in Q4 2023 and said topline data could be available as early as Q1 2024.
- The Phase 2 AMP-270 locally advanced pancreatic cancer trial was recruiting. The company estimated Amarex’s trial-management work at approximately $8.4 million and an anticipated duration of about 4.6 years; the estimate excludes certain third-party, investigator, and escalation costs. A separate Erasmus MC study with AstraZeneca received required Dutch approvals.
- Ampligen’s FDA application for ME/CFS received a Complete Response Letter in 2013; further clinical and other work is required. Argentine commercial launch also remained pending final regulatory inspection and product release testing. Production of Alferon N Injection API was on hold, with no definitive restart timetable.
- Manufacturing and trial spending are material: the company paid approximately $1.433 million to Jubilant for Ampligen production and approximately $1.266 million to Amarex for ongoing agreements during the nine months. Management said a product purchase contributed about $1.4 million of increased spending and was not expected to recur normally.
- Clinical efficacy, regulatory approvals, manufacturing readiness, product supply, and the ability to obtain partners or funding remain significant uncertainties. Management cautioned that trial results may not be successful and actual funding needs may exceed expectations.
- Litigation is a notable expense and uncertainty. In the BioLife matter, a September court order left only the defendant’s counterclaim proceeding; AIM sought permission for an immediate appeal. The company also reported shareholder-related federal and Delaware litigation, including a pending Delaware Court of Chancery matter concerning bylaws and director nominations. Outcomes and potential legal costs are uncertain.
- On October 16, 2023, after quarter-end, AIM engaged Azenova to support business-development efforts aimed at a partnership, out-license, or other transaction for Ampligen.
Most important facts for investors to verify
- Cash burn and runway: compare actual subsequent cash use and financing with management’s approximately 16-month estimate.
- AMP-518 dosing completion and timing and quality of reported topline results; separately track AMP-270 enrollment, cost, and timeline.
- Progress toward Argentine commercial release and any update on the FDA-required work for Ampligen or Alferon manufacturing and approval.
- Whether AIM obtains a development or commercialization partner, and whether additional financing is required; assess potential dilution from equity sales and outstanding equity awards.
- Developments and possible costs in the BioLife and shareholder litigation, and the effect of professional fees on operating expenses.